Fanconi anemia complementation group D1 (BRCA2-related Fanconi anemia)

Prime Editing (PE5max/PEmax) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Fanconi anemia complementation group D1 (BRCA2-related Fanconi anemia) targeting the BRCA2 c.8487G>C (p.Gln2829His) variant (Pathogenic, missense variant, non-coding transcript variant). The editing system (PEmax with engineered pegRNA) search-and-replace editing that directly rewrites the pathogenic transversion back to wild-type without requiring DSBs. Target tissue: Blood/HSC. Therapeutic goal: Correct BRCA2/FANCD1 loss-of-function variants in hematopoietic stem cells at the BRCA2 locus to restore homologous recombination DNA repair, prevent bone marrow failure, and reduce early-onset leukem. Risk profile: off-target Low (prime editing has inherently low off-target rate), delivery complexity Low, immunogenicity Low.

1. Molecular basis: BRCA2 NM_000059.4(BRCA2):c.8487G>C (p.Gln2829His) is classified as Pathogenic (ClinVar variation ID 4687466). Molecular consequence: missense variant, non-coding transcript variant. Protein change: Q1185H, Q2797H, Q2829H, Q690H. 2. Epidemiology: Fanconi anemia overall has an estimated prevalence between 1 in 100,000 and 1 in 350,000 live births, with higher incidences in certain founder populations (WEB-04). It is usually inherited in an autosomal recessive manner with more than 20 genes implicated including BRCA2/FANCD1 (WEB-04). BRCA2/FAN 3. Standard of care: Guidelines and Orphanet describe Fanconi anemia as a bone marrow failure and cancer predisposition syndrome characterized by growth deficiency, congenital malformations, progressive bone marrow failure typically presenting in the first decade, and markedly increased risk of myelodysplastic syndrome, 4. Pipeline: ClinicalTrials.gov and rare-disease foundations document multiple HSCT optimization studies and ex vivo gene therapy trials for Fanconi anemia, primarily focusing on FANCA but demonstrating platform feasibility. An early and subsequent Phase I/II lentiviral gene-therapy program (e.g., NCT04248439 an 5. Prime editing validation: PEmax (Chen et al. 2021, Cell) enables precise insertions, deletions, and all 12 point mutations without DSBs. Prime Medicine is advancing PE programs into clinical development. LNP and dual-AAV delivery of PE have been demonstrated in preclinical liver and CNS models.

1. No published data specifically correcting BRCA2 c.8487G>C (p.Gln2829His) with Prime Editing (PE5max/PEmax); strategy is based on general principles and must be validated preclinically. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

For BRCA2 c.4459A>T (p.Lys1487Ter), a pathogenic nonsense variant that abolishes BRCA2-mediated homologous recombination repair and causes Fanconi anemia complementation group D1 (FA-D1), ex vivo CRISPR-mediated gene correction in autologous HSPCs represents a promising therapeutic strategy that exploits a unique biological advantage: corrected FA HSPCs have a strong proliferative advantage over uncorrected cells in the bone marrow, meaning that even low editing efficiency can lead to progressive clonal expansion of corrected cells post-transplant. FA-D1 is among the most severe FA subtypes, with early-onset bone marrow failure, extreme cancer predisposition (medulloblastoma, Wilms tumor, AML by age 5), and hypersensitivity to DNA crosslinking agents.

The selective advantage of gene-corrected FA HSPCs has been demonstrated in multiple preclinical models and in naturally occurring somatic mosaicism in FA patients, where revertant HSPCs expand to dominate hematopoiesis over time (Gregory et al., 2001; Gross et al., 2002). This means that even modest initial correction rates can achieve therapeutic engraftment. Lentiviral BRCA2 gene addition in FA-D1 patient-derived cells has restored mitomycin C resistance in vitro. However, the BRCA2 cDNA (~10.3 kb) far exceeds both AAV and standard lentiviral packaging limits, making gene addition challenging. CRISPR-mediated correction of the specific nonsense variant (A-to-T reversion at c.4459) via prime editing or base editing is therefore attractive as it modifies only the pathogenic nucleotide. FA HSPCs are inherently fragile — they are hypersensitive to DNA damage, making standard gene editing (which induces double-strand breaks) potentially genotoxic. Cas9-free approaches (base editors, prime editors) that avoid DSBs are therefore strongly preferred.

FA HSPCs are notoriously difficult to culture ex vivo — they exhibit accelerated senescence, DNA damage sensitivity, and poor expansion compared to normal HSPCs. This limits the cell numbers available for editing and transplantation. Standard CRISPR-Cas9 nuclease-mediated editing is particularly hazardous in FA cells because the Fanconi pathway is required for repair of DSB intermediates — Cas9-induced breaks in BRCA2-deficient cells may trigger p53-mediated apoptosis or chromosomal instability. Base editors (which avoid DSBs) are preferred but require specific PAM and editing window constraints that may not align with every variant. For p.Lys1487Ter (A>T transversion), correcting back to lysine (AAG) requires a T-to-A transversion — neither ABE nor CBE can perform this directly. Prime editing could install the correction but has lower efficiency in primary HSPCs. The cancer predisposition in FA-D1 means that any residual uncorrected cells with biallelic BRCA2 loss remain at high risk of malignant transformation. Conditioning regimen toxicity is amplified in FA patients due to their DNA repair deficiency — reduced-intensity conditioning is mandatory.